<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767415</url>
  </required_header>
  <id_info>
    <org_study_id>1106011772</org_study_id>
    <nct_id>NCT01767415</nct_id>
  </id_info>
  <brief_title>Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether stereotactic indigo carmine injection
      can safely increase the extent of tumor resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Extent of Resection</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the extent of resection of the tumor following the indigo carmine infusion to the tumor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of complications after injection</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain Tumors With Ill-defined Margins</condition>
  <arm_group>
    <arm_group_label>Indigo Carmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative stereotactic injection of Indigo Carmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indigo carmine</intervention_name>
    <arm_group_label>Indigo Carmine</arm_group_label>
    <other_name>Indigotindisulfonate sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with gliomas or other tumors that may have ill defined margins during the
             operative resection.

        Exclusion Criteria:

          -  Subjects with a contraindication for brain MRI scan.  Subjects who are pregnant,
             younger than 18 years old or have a contraindication for indigo carmine are excluded
             as well
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Konstantinos Margetis, MD</last_name>
    <phone>212-746-2363</phone>
    <phone_ext>2</phone_ext>
    <email>kom2001@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamika Wong</last_name>
    <phone>212-746-1788</phone>
    <email>taw2015@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College Department of Neurological Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Margetis, MD</last_name>
      <email>kom2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Greenfield, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Margetis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 10, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Theodore H. Schwartz</investigator_full_name>
    <investigator_title>Professor of Neurological Surgery</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
